@mikeehrenstein.bsky.social
📤 32
📥 13
📝 5
Professor of Rheumatology at UCL
Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE
@shipam.bsky.social
@versusarthritis.bsky.social
www.thelancet.com/journals/lan...
loading . . .
Revisiting safety and refining benefit of rituximab–belimumab combination for refractory SLE
B-cell depletion using rituximab is used to treat systemic lupus erythematosus (SLE), particularly for patients whose disease is refractory to conventional immunosuppressants (eg, mycophenolate), and ...
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913%2825%2900256-5/fulltext
about 2 months ago
0
3
2
reposted by
4 months ago
@arrdept-ucldom.bsky.social
Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted
doi.org/10.1016/j.xc...
Builds on theranostic discovery
doi.org/10.1016/S266...
On BEAT-Lupus
doi.org/10.7326/M21-...
Lupus ≠ one-size-fits-all
doi.org/10.1084/jem....
0
7
2
reposted by
UCL Dept of Aging, Rheumatology & Regenerative Medicine
4 months ago
So fantastic to see this work out
@shipam.bsky.social
, with Prof Michael Ehrenstein and Dr Dan McCluskey. This new departmental paper shows the utility of anti-dsDNA IgA2 and IgA2+ B cells as a biomarker for response to Belimumab in SLE. Read in
@cp-cell.bsky.social
journal - Cell Reports Medicine.
add a skeleton here at some point
1
11
3
www.nihr.ac.uk/story/strati...
a big thank you to the lupus specialists and their patients who made this research possible
loading . . .
https://www.nihr.ac.uk/story/stratify-lupus-personalised-care-patients
7 months ago
0
1
1
www.independent.co.uk/news/health/...
loading . . .
Simple blood test offers new hope to lupus patients
Up to 69,000 people in the UK have lupus, a chronic autoimmune condition
https://www.independent.co.uk/news/health/lupus-sympotoms-nhs-blood-test-treatment-b2747367.html
7 months ago
0
2
1
STRATIFY lupus is a newly funded precision medicine biomarker enrichment trial funded by
@versusarthritis.bsky.social
and
@nihr.bsky.social
with support from
@glaxosmithkline.bsky.social
in collaboration with
@shipam.bsky.social
& many UK lupus specialist centres. Will start recruitment early 2026.
8 months ago
0
4
3
you reached the end!!
feeds!
log in